Figure 1
The percentage of onset of viral clearance (SARS-CoV-2 PCR negative conversion) in the two COVID-19 study groups; Group 1 (hydroxychloroquine and oseltamivir) and Group 2 (favipiravir) within 2 weeks of treatment.
Figure 1 | Scientific Reports
